Stars

Stop a Pandemic.
Start a Movement.

We founded Pardes in 2020 to cultivate change and help lead the way to a post-pandemic future.

Trees Mobile Graphics
Telescope
Grass Dark

MISSION & VISION

We are on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

Our vision is to cultivate change for a post-pandemic world.

Tree
Telescope
Grass

LEADERSHIP

A Shared Passion for Solving Pandemic-Sized Problems

To cultivate the change that we believe is needed, Pardes has assembled an experienced Management Team, Board of Directors, and Strategic Advisors, and is rapidly growing our team. Collectively, we bring together decades of experience discovering, developing, and commercializing a broad range of therapeutics. More importantly, we share a commitment to innovating the biopharma business model as we attempt to solve some of the world’s most pressing health challenges.

Management Team

Tom Wiggans

Chief Executive Officer & Chair of the Board

Tom brings over 40 years of experience in the biopharmaceutical industry, including over 25 years of chief executive leadership. He most recently served as Chief Executive Officer and Chairman of the Board of Directors of Dermira, Inc. which he co-founded in 2010, until its acquisition by Eli Lilly in 2020 for $1.1 billion. Prior to founding Dermira, Tom served as Chief Executive Officer and Chairman of the Board of Directors of Peplin, Inc. until its acquisition by LEO Pharma A/S in 2009. He also has served as Chief Executive Officer and Chairman of the Board of Directors of Connetics Corporation and in various other executive positions at CytoTherapeutics Inc. and Ares-Serono S.A. Tom began his career in the industry with Eli Lilly and Company.

Tom holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

Uri Lopatin, MD

Chief Scientific & Strategic Advisor
Board Member and Founder

Uri is a biotech entrepreneur and has worked in various executive clinical and translational science positions for esteemed organizations, including Schering Plough, Roche, Gilead Sciences, and Y Combinator where he served as a visiting partner. He also co-founded Assembly Pharmaceuticals, functioning as both Chief Medical Officer and Vice President of Research, and successfully raising over $300 million to move two first-generations of novel therapeutics for hepatitis B into global Phase 1 and Phase 2 clinical studies. Uri has published and patented broadly in virology and immunology.

Uri received a BA in Biology from Cornell University and MD degree at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School. He completed his residency at New York University Medical Center, internship at the University of Washington, and fellowship training in Infectious Disease at the National Institutes of Health.

Brian Kearney, PharmD

Chief Development Officer

Brian is a veteran of antiviral drug development in HIV, HBV, and HCV. He spent over two decades at Gilead Sciences working to advance and lead successful development programs for multiple compounds from Phase 1 through Phase 3 clinical studies. Brian formed Gilead’s clinical pharmacology functional area and led first-in-franchise global registrations, including the breakthrough standard of care treatment of HCV with SOVALDI®. His contributions have led to the approval of more than fifteen new drugs.

Brian earned a PharmD degree from the University of Illinois at Chicago. He performed his residency at the University of Pittsburgh and completed a post-doctoral research fellowship at the University of California San Francisco, with a focus on Antiviral Drug Research.

Heidi Henson

Chief Financial Officer

Heidi has over two decades of financial operations experience with both public and private companies. Before Pardes, she served as Chief Financial Officer for Imbria Pharmaceuticals, Kura Oncology, Intellikine (acquired by Takeda), Wellspring Biosciences, and their parent company, Araxes Pharma. Heidi has guided various companies through early-stage start-up activities, SEC reporting, and Sarbanes-Oxley implementation and compliance. She began her career in auditing at PricewaterhouseCoopers. She currently serves on the board of directors of PepGen and Cend Therapeutics.

Heidi received a BS in Accounting from the University of San Diego and is a Certified Public Accountant (inactive) in California.

Philippe Tinmouth

Chief Business & Strategy Officer

Phil has over 25 years of experience in strategic leadership, business development and alliance management in the biopharmaceutical industry. He served in various positions at Vertex Pharmaceuticals, most recently as Vice President and Head of Business Development & Alliance Management where he was directly involved in every Vertex transaction and collaboration from July 2013 through December 2021. Phil also held positions at Bain & Company, where he advised pharmaceutical and biotechnology companies. He currently mentors biotech start-ups at Harvard Innovation Lab and the Canadian Technology Accelerator. Phil currently serves on the board of directors of Scynexis, Inc.

Phil holds a BS degree in Mechanical Engineering from Queen's University, where he graduated with honors. He also earned an MBA from Harvard Business School.

Sean Brusky

Chief Commercial Officer

Sean brings over two decades in biopharmaceutical business development, commercial, managed care, and medical affairs experience. He was Head of Healthcare Delivery Innovation for Genentech, Inc. (a member of the Roche Group), responsible for standing up novel multi-stakeholder partnerships in virtual clinical trials, personalized medicine, point-of-care, home-based diagnostics, telemedicine, and digital health. In earlier roles, Sean assembled and led teams responsible for brand-focused marketing and sales spanning multiple products. Prior to Genentech, Sean was part of the business development team at Vertex Pharmaceuticals focused on global corporate development, partnering and out-licensing of antivirals and other therapeutics. Sean serves as a board advisor to early-stage healthcare delivery transformation ventures.

Sean earned his BS degree in Biochemistry & Molecular Biology from Brown University and MBA degree from Harvard Business School.

Elizabeth Lacy, JD

General Counsel & Corporate Secretary

Elizabeth has over 25 years of legal experience. Prior to Pardes, she was the General Counsel, Senior Vice President of Legal Operations, and Corporate Secretary for Assembly Biosciences. During her tenure, she built the legal team that supported operations and advised on corporate governance, SEC reporting, equity offerings, compliance, and operational matters related to the pre-clinical stage to clinical-stage company transition. Elizabeth has worked in various legal areas throughout her career, including venture capital, private equity, and asset-based lending.

Elizabeth earned a BA degree in Public Policy from Duke University and a JD, summa cum laude, degree from Case Western Reserve University.

Ann Kwong, PhD

Executive Vice President, Research

Ann has over 30 years of experience in in the biopharmaceutical industry and has helped move multiple antiviral compounds into the clinic. At Vertex Pharmaceuticals, Ann played a leading role in the research, development, and commercialization of telaprevir, an HCV protease inhibitor that received the Prix Galien Award for Best Pharmaceutical Agent in 2012. Ann also designed Vertex’s influenza virus program, which led to the development of pimodivir, a first in class PB2 inhibitor; she was awarded the Gertrude Elion Memorial Award in 2020 by the International Society for Antiviral Research. Ann founded Trek Therapeutics to develop affordable HCV treatments; most recently she was the EVP of R&D at Dewpoint Therapeutics. Ann is a co-author or inventor on numerous publications and patents.

Ann received her BA degree in Biology and PhD degree in Virology from the University of Chicago.

Valdas Jurkauskas, PhD

Senior Vice President, Technical Operations

Valdas specializes in pharmaceutical manufacturing, clinical and commercial drug supply and enabling transition from clinical stage into commercialization.

Prior to Pardes, Valdas was a key member of the teams that commercialized antiviral INCIVEK® with Vertex Pharmaceuticals, antibiotic ZERBAXA® with Cubist Pharmaceuticals (acquired by Merck) and anemia treatment VAFSEO® with Akebia Therapeutics. Valdas also led the Technical Operations team at STA Pharmaceutical, a WuXi AppTec company, responsible for clinical supplies and commercial production. Valdas is a co-inventor of 20 US-issued patents.

Valdas holds a PhD degree in Organic Chemistry from the Massachusetts Institute of Technology and a BS degree in Chemistry with honors from the University of Toronto.

Lee Arnold, PhD

Senior Scientific Advisor

Over the course of his career, Lee has held various leadership roles in pharma and biotech, including Pfizer, Kinnate Biopharma, and Coferon. While working at Assembly Biosciences, he co-invented vebicorvir and ABI-H2158 for hepatitis B. Throughout the years, Lee has played an integral role in delivering 13 IND-track drug candidates to development in oncology and virology, including numerous first-in-class drugs like TARCEVA® (erlotinib) for non-small cell lung cancer. Lee is an inventor with over 85 patent applications and co-author on 38 peer-reviewed papers.

Lee received a BS in Chemistry, with honors, at the University of Waterloo and a PhD degree in Organic Chemistry from the University of Alberta.

Board of Directors

Tom Wiggans

Chief Executive Officer & Chair of the Board

Tom brings over 40 years of experience in the biopharmaceutical industry, including over 25 years of chief executive leadership. He most recently served as Chief Executive Officer and Chairman of the Board of Directors of Dermira, Inc. which he co-founded in 2010, until its acquisition by Eli Lilly in 2020 for $1.1 billion. Prior to founding Dermira, Tom served as Chief Executive Officer and Chairman of the Board of Directors of Peplin, Inc. until its acquisition by LEO Pharma A/S in 2009. He also has served as Chief Executive Officer and Chairman of the Board of Directors of Connetics Corporation and in various other executive positions at CytoTherapeutics Inc. and Ares-Serono S.A. Tom began his career in the industry with Eli Lilly and Company.

Tom holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

Uri Lopatin, MD

Chief Scientific & Strategic Advisor
Board Member and Founder

Uri is a biotech entrepreneur and has worked in various executive clinical and translational science positions for esteemed organizations, including Schering Plough, Roche, Gilead Sciences, and Y Combinator where he served as a visiting partner. He also co-founded Assembly Pharmaceuticals, functioning as both Chief Medical Officer and Vice President of Research, and successfully raising over $300 million to move two first-generations of novel therapeutics for hepatitis B into global Phase 1 and Phase 2 clinical studies. Uri has published and patented broadly in virology and immunology.

Uri received a BA in Biology from Cornell University and MD degree at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School. He completed his residency at New York University Medical Center, internship at the University of Washington, and fellowship training in Infectious Disease at the National Institutes of Health.

Mark Auerbach

Board Member

Mark has 20 years of experience working as an independent director for pharma and biotech, including Assembly Bio, Optimer, and Par Pharmaceutical. Mark was both Chairman of the Audit Committee and a member of the Compensation Committee for Assembly Bio. Mark was also Lead Independent Director and then Non-Executive Chairman of Par. He was the Lead Independent Director and Chairman of the Audit Committee at Optimer and Chairman of Neuro-Hitech.

Mark received a BS degree in Accounting from Rider University.

Deborah M. Autor, JD

Board Member

Deborah brings extensive pharmaceutical and regulatory experience to Pardes. Deb served as Vice President, Global Head of Regulatory Excellence at AstraZeneca, where she led Regulatory Operations, Policy, and Intelligence for the company’s submissions globally. Deb held various positions for Mylan NV, including Head of Strategic Global Quality and Regulatory Policy. She also worked for the Food and Drug Administration in different roles, ending her distinguished tenure as Deputy Commissioner, Global Regulatory Operations & Policy. She serves on many committees, including the Centre for Innovation in Regulatory Science – Scientific Advisory Council and the U.S Pharmacopoeia Quality Institute – Advisory Board.

Deb received a BA degree in Psychology from Columbia University and a JD, magna cum laude, degree from Boston University School of Law.

Laura J. Hamill

Board Member

Laura is an experienced professional with years of expertise in global commercial operations and strategic planning. Her career history spans decades and has included diverse roles, including Executive Vice President, Worldwide Commercial Operations at Gilead Sciences. Laura also worked in various roles at Amgen, including Senior Vice President, U.S Commercial Operations. She currently serves on the board of directors of numerous companies, including Anaptysbio, Y-mAbs Therapeutics, and Acceleron Pharma.

Laura holds a BS in Business Administration from the University of Arizona.

Jay Lobell

Board Member

Jay brings a diverse skill set with years of experience ranging from regulatory, transactional, and litigation matters to commercial real estate and healthcare. He is currently the CEO and Co-Founder of GMF Capital, a private equity investment firm. Jay also co-founded and served as Vice Chairman of Beech Street Capital, a Department of Housing and Urban Development lender acquired by Capital One Bank. Jay started his career at Covington & Burling LLP, a national law firm, where he advised companies and individuals. He currently serves on the board of directors of Fortress Biosciences and several privately held healthcare operating companies.

Jay received a BA, summa cum laude, from the City University of New York and a JD from Yale University Law School, where he was Senior Editor of the Yale Law Journal.

James B. Tananbaum, MD

Board Member

Jim brings extensive experience in healthcare investment strategy. He is the Founder and Chief Executive Officer of Foresite Capital, a US-focused healthcare investment firm with more than $4 billion in assets under management. He has been a thought partner to some of the most impressive fast-growth companies over the last three decades, including 10x Genomics, Amerigroup, and Jazz Pharmaceuticals. Jim is a five-time Midas List honoree, a coveted accolade for the world's top venture capital investors.

Jim earned a BS and BSEE degree in Applied Math and Electrical Engineering/Computer Science degree from Yale University. He received a MD degree from Harvard/MIT Health Sciences and Technology Program. He received a MBA degree from Harvard Business School.

Mike Varney, PhD

Board Member & Scientific Advisory Board

Mike has been a leader for some of the best companies in the biotech, including Genentech, Inc. (a member of the Roche Group) and Pfizer. As the former Executive Vice President and Head of Genentech Research and Early Development, he was responsible for all aspects of Genentech R&D’s early innovation, drug discovery, and development of drug candidates. He also served as a member of the Roche Corporate Executive Committee. Early in his career, Mike was one of the original fifteen employees at Agouron, a biotech company that developed protein structure-based drug design as a new drug discovery approach. He currently serves on the board of directors of Erasca, Inc.

Mike received a BS degree in Chemistry from the University of California Los Angeles, a PhD degree in Synthetic Organic Chemistry from the California Institute of Technology, and was an American Cancer Society Post-Doctoral Fellow at Columbia University.

Strategic Advisors

Kenneth Bernard, MD

Scientific Advisory Board

A Rear Admiral (USPHS, Ret.), Kenneth has served the US government as a strategic health security expert in various roles over his dedicated career, working in several presidential administrations. He was appointed Special Assistant to the President for Homeland Security and Assistant Surgeon General, in charge of biodefense policy, where he negotiated a $5.6 billion bill to fund vaccines and antivirals against biothreats. He also served as Senior Political Adviser to the Director-General of the World Health Organization. He currently works as an advisor to US government agencies and the private sector on issues of biodefense, intelligence, and pandemics, including COVID-19. He is a member of the Council on Foreign Relations and the National Science Advisory Board for Biosecurity.

Kenneth received a BS degree in Tropical Studies from the University of California Berkeley and a MD degree from the University of California Davis. He earned a DTM&H from the London School of Hygiene and Tropical Medicine and completed an Epidemic Intelligence Service Fellowship at the Centers for Disease Control and Prevention.

Mike Varney, PhD

Board Member & Scientific
Advisory Board

Mike has been a leader for some of the best companies in the biotech, including Genentech, Inc. (a member of the Roche Group) and Pfizer. As the former Executive Vice President and Head of Genentech Research and Early Development, he was responsible for all aspects of Genentech R&D’s early innovation, drug discovery, and development of drug candidates. He also served as a member of the Roche Corporate Executive Committee. Early in his career, Mike was one of the original fifteen employees at Agouron, a biotech company that developed protein structure-based drug design as a new drug discovery approach. He currently serves on the board of directors of Erasca, Inc.

Mike received a BS degree in Chemistry from the University of California Los Angeles, a PhD degree in Synthetic Organic Chemistry from the California Institute of Technology, and was an American Cancer Society Post-Doctoral Fellow at Columbia University.

Carol Brosgart, MD

Scientific Advisory Board

Carol has spent decades as a leader and advisor to industry, public health, government, and academia. She has worked for world-renowned organizations, including as CMO of UCSF Benioff Children’s Hospital, CMO of Alios BioPharma, and an executive at Gilead Sciences. While Vice President of Clinical Research at Gilead, she led the development and worldwide regulatory approval for two antiviral therapies: VIREAD® for HIV and HEPSERA® for chronic hepatitis B. She has also served on advisory committees for the CDC and Health and Human Services. She is a Clinical Professor of Medicine, Biostatistics, and Epidemiology at the University of California San Francisco.

Carol received a BS degree in Community Medicine from the University of California Berkeley and a MD degree from the University of California San Francisco, where she completed her residency training in Pediatrics. She also completed residency training in Public Health and Preventive Medicine at University of California Berkeley. She has published extensively in the area of infectious diseases.

Brad Jenkins

Commercial Advisory Board

Brad recently retired from Roche, where he was Vice President of Influenza for Genentech, Inc. (a member of the Roche Group), leading commercial, medical, and government affairs teams supporting TAMIFLU® and XOFLUZA®. Brad was also VP of Sales and Marketing, National Sales Director, Life Cycle Leader, and Global Marketing Lead. His work has had an impact on HCV, HBV, CMV, and influenza. Brad provides advisory services for the healthcare industry, supporting projects involving therapies for viruses and their application to public health and pandemic preparedness.

Brad received a BS degree in Electrical Engineering from Ohio State University.

Clifford Samuel

Commercial Advisory Board

Clifford has 25 years of commercial leadership experience in the biopharmaceutical industry, with more than two decades at Gilead Sciences in leadership roles across sales, managed markets, global health policy, and global commercial operations. Propelled by his mission to ensure access to life-saving medicines, he identified market potential and enabled the delivery of medicines to 19 million living with HIV/AIDS in over 134 resource-challenged countries. Clifford leverages his operational excellence skills, knowledge of the regulatory landscape, and worldwide distribution network.

Clifford earned his BS degree in Mechanical Engineering from the New Jersey Institute of Technology. He is a recipient of an Edward F. Weston Medal for Professional Achievement and is a member of the American Institute for Medical and Biological Engineering. Clifford is internationally-recognized for significant advancements in engineering.

Robert Zamboni, PhD

Scientific Advisory Board

Robert has over 40 years of drug discovery experience. At Merck Frosst-Canada, he was instrumental in developing SINGULAIR®, which helped millions of patients suffering from asthma and allergic rhinitis. He also significantly contributed to the development of VIOXX®, a selective COX2 inhibitor for inflammation and pain. Robert rose from Bench Chemist to Vice President of MedChem at Merck Frosst and was involved in over two dozen programs. After retiring from Merck Frosst, he started ZCS, a consulting company that has provided strategic direction to over 50 drug discovery programs.

Robert received a BS degree in Honors Chemistry and a PhD degree in Organic Synthesis from McGill University and completed postdoctoral fellowships at the University of Pittsburgh and Yale University. Robert is the recipient of multiple awards and prizes, including the Lionel Boulet Prize (Prix du Québec), the Prix Galien, and the Heroes of Chemistry award.